Immune system – no discrete molecular pharmacological target

The classification 'Immune system – no discrete molecular pharmacological target' refers to a systemic pharmacological entity where the therapeutic effect is achieved through the broad modulation of immune pathways rather than a single molecular receptor or enzyme (Gaulton et al., 2017, Nucleic Acids Res). This designation is commonly found in databases like ChEMBL to describe agents such as vaccines, non-specific immunomodulators, and certain biologics that trigger a multi-faceted physiological response (IUPHAR/BPS Guide to Pharmacology). The immune system's primary biological role is to protect the host from pathogens and malignancy through a complex network of innate and adaptive components (Murphy & Weaver, 2016, Janeway's Immunobiology). In disease contexts, this system may be dysregulated, contributing to chronic inflammation, autoimmunity, or susceptibility to infection and cancer. Drugs mapped to this category aim to recalibrate these systemic responses, often by stimulating cytokine production or enhancing antigen presentation across various cell populations. Due to the lack of a discrete molecular target, these therapies can present unique safety challenges, including systemic inflammatory responses and off-target immune activation (StatPearls, 2023).

Other names

Immune systemSystemic immunomodulationNon-specific immune targetSystemic immune response

Systemic modulation of immune cell activity, cytokine production, and signaling pathways without binding to a single, discrete molecular receptor or enzyme.